Catalyst hopes to catch a break in more rare diseases, while phase II success could support Oxurion’s reinvention.
With only 18 novel drugs approved by the FDA so far this year, the influential US regulator looks set to dim the green lights in 2019.
A strong second quarter pushed Novartis’s stock up 5% this morning, but Kymriah continues to look weak, and the jury is still out on Zolgensma.
The overall rate of device approvals in 2019 is holding steady on last year – but the types of approvals are different.
Up-front fees paid out by biopharma companies to seal licensing deals noticeably dipped in the second quarter of the year – then Gilead and Galapagos came along.
Continued interest in the Sting pathway might come as a surprise, though secrecy suggests that asset prices are failing.
For $5bn up front Gilead has effectively gained access to the Belgian company’s pipeline, in a deal that will tie the US biotech to Galapagos for many years to come.
Neon's cancer vaccine makes a decent early showing, but overall survival remain a crucial measure.
Most medtechs that listed this year priced their IPOs at a premium, and most saw their shares appreciate.
Neon Therapeutics is due to unveil the first rigorous test of its neoantigen approach to fighting tumours, while Neurotrope makes a brave bid in Alzheimer's.
The second quarter saw start-ups raise the smallest venture capital haul in two years, as the number of mega rounds declined.
Weaker than expected generic erosion of its key Suboxone film product has allowed Indivior to raise full-year guidance.
The first one-shot billion-dollar venture investment round in the medical technology sector has gone to Verily as computing bleeds into medicine.
The Medicines Company needs to show decent efficacy and pristine safety with its long-lasting PCSK9 inclisiran to stand a chance of disrupting the market.
The UK biotech gets a big boost from the sale of a pan-Raf inhibitor to Jazz Pharmaceuticals, but Redx’s money worries are far from over.
The second mega-merger in as many quarters means a huge M&A year is in the making, but a look at deal volume tells another story.
Probiodrug changes its name to Vivoryon and expands its focus to include oncology, but insists that it is still first and foremost an Alzheimer’s company.
Hopes for lumateperone rest on schizophrenia as bipolar data raise questions.